EP
BPMC

Essential Partners’s Blueprint Medicines BPMC Stock Holding History

Essential Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-878
Closed -$113K – 2685
2025
Q2 		$113K Buy
+878
New +$91.2K 0.04% 340

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Essential Partners's BPMC Position: Q3 2025 in Review

Essential Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 878 shares — an estimated $113K sold.

Essential Partners first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $113K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Essential Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 878 Blueprint Medicines shares in Q3 2025, an estimated $113K.
  • Essential Partners first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Blueprint Medicines position peaked at $113K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.